BIIB vs BIO: fair value comparison
Biogen Inc. and Bio-Rad Laboratories, Inc. · Updated 2026-09-06
BIIB currently screens as fairly valued while BIO screens as overvalued. Within Healthcare, BIIB currently sits closer to the top of our discount ranking.
| BIIB | BIO | |
|---|---|---|
| Verdict | Fairly valued | Overvalued |
| Last price | $220.83 | $330.01 |
| 12-month range | $151.44–$216.04 | $256.55–$380.96 |
| Sector rank | #86 of 113 Healthcare | #88 of 113 Healthcare |
| Quality grade | B | B |
| Leverage | Low | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: BIIB fair value analysis · BIO fair value analysis